Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;80(8):1113-1120.
doi: 10.1007/s00228-024-03686-6. Epub 2024 Apr 10.

Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials

Joseph P Rindone  1 , Chadwick K Mellen  2
Affiliations
Review

Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials

Joseph P Rindone et al. Eur J Clin Pharmacol. 2024 Aug.

Abstract

Purpose: The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) in patients with heart failure with reduced ejection fraction (HFrEF).

Methods: The databases of PubMed and EMBASE were used to identify those randomized controlled trials which compared SV to ARB/ACEI in patients with HFrEF. Only those trials that reported outcomes regarding total mortality, cardiovascular mortality, and worsening heart failure were considered. Meta-analysis was performed separately in those patients receiving equivalent doses of ARB/ACEI and those receiving sub-equivalent doses. Equivalent doses were SV 97/103 = valsartan 160 mg twice daily = enalapril 20 mg twice daily = ramipril 5 mg twice daily. Meta-analyses were performed using Review Manager 5.4.

Results: Twelve randomized trials were identified involving 17,484 patients: 11,291 in the sub-equivalent group (8 trials) and 6193 in the equivalent group (4 trials). Meta-analyses showed there were no statistical differences regarding the outcomes of total mortality, cardiovascular mortality, and worsening heart failure in the equivalent dosing group. However, SV reduced total mortality (risk ratio (RR) = 0.85, 95% confidence interval (CI) = 0.78-0.93, p < 0.001), cardiovascular mortality (RR = 0.81, 95% CI = 0.73-0.90, p ≤ 0.001) and worsening heart failure (RR = 0.77, 95% CI = 0.64-0.92, p = 0.005) in the sub-equivalent group.

Conclusion: When compared to equivalent doses of ARB/ACEI, SV is not superior in reducing mortality and worsening heart failure. SV is superior when compared to sub-equivalent doses of ACEI.

Keywords: Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitor; Heart failure; Sacubitril/valsartan.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Heidenreich PA, Bozkurt B (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc2021.12.012 - DOI - PubMed - PMC
    1. McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004 - DOI - PubMed
    1. Ahn R, Prasad V (2018) Do limitations in the design of Paradigm-HF justify the slow real world uptake of sacubitril/valsartan (Entresto)? Cardiovasc Drugs Ther 32:633–635 - DOI - PubMed
    1. Yandrapalli S, Aronow WS, Mondal P et al (2017) Limitations of sacubitril/valsartan in the management of heart failure. Am J Therap 24:e234–e239 - DOI
    1. Bernardez-Pereira S, Alvares-Ramires FJ, Tavares de Melo RF et al (2018) Was the enalapril dose too low in the PARADIGM-HF trial? Cardiol Rev 26:196–200 - DOI - PubMed

MeSH terms

LinkOut - more resources